Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 1:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 76 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Schizophreniform Disorder Clear all
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Clonazepam Effects on Brain Oscillations and Cognition in Schizophrenia

NCT03061136
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions
Clonazepam, Placebo
Drug
Lead sponsor
Palo Alto Veterans Institute for Research
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 21, 2026, 1:43 PM EDT
Completed Phase 4 Interventional Results available

Varenicline Adjunctive Treatment in Schizophrenia

NCT00492349
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions
Varenicline, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 60 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
3
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 5, 2022 · Synced Oct 21, 2026, 1:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Enhancing Cognitive Training Through Exercise After a First Schizophrenia Episode

NCT02267070
View directory record Official record
Conditions
Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder
Interventions
Case management and supportive psychotherapy, Family psychoeducation, Cognitive training, Aerobic exercise
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Oct 21, 2026, 1:43 PM EDT
Completed Phase 2 Interventional Results available

A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase Schizophrenia

NCT02008773
View directory record Official record
Conditions
Schizophrenia
Interventions
Valacyclovir HCI 500 mg tablets, placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 40 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
13
States / cities
Bellflower, California • Los Angeles, California • Riverside, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Oct 21, 2026, 1:43 PM EDT
Withdrawn Not applicable Interventional

Transcranial Direct Current Stimulation for Hallucinations in First-Episode Schizophrenia

NCT02661347
View directory record Official record
Conditions
Schizophrenia, Schizophreniform, Schizoaffective Disorder, Psychosis Not Otherwise Specified (NOS)
Interventions
Risperidone, tDCS
Drug · Device
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 40 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Oct 21, 2026, 1:43 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Neural Oscillations as Genetic and Functional Biomarkers in Normal and Disease States

NCT01425671
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions
Not listed
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
14 Years to 62 Years
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 26, 2024 · Synced Oct 21, 2026, 1:43 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia

NCT00330551
View directory record Official record
Conditions
Schizophrenia
Interventions
Oral Risperidone, Risperidone in Long-Acting Injectable Form (Consta)
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 45 Years
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Oct 21, 2026, 1:43 PM EDT
Completed Not applicable Interventional Results available

Clinical Trial of Dipyridamole in Schizophrenia

NCT00349973
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions
Dipyridamole, Olanzapine
Drug · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Oct 21, 2026, 1:43 PM EDT
Completed Phase 2 Interventional Results available

N-Acetyl-Cysteine (NAC) in Early Phase Schizophrenia Spectrum Psychosis

NCT01354132
View directory record Official record
Conditions
Schizophrenic Psychoses
Interventions
n-acetylcysteine, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 35 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 5, 2017 · Synced Oct 21, 2026, 1:43 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Adult Study Oxytocin - Behavioral

NCT02567032
View directory record Official record
Conditions
Schizophrenia, Oxytocin, Social Cognition, Psychotic Disorders
Interventions
Oxytocin, Saline Nasal Spray
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
324 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2019
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Oct 21, 2026, 1:43 PM EDT
Completed Phase 4 Interventional Results available

Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)

NCT00053703
View directory record Official record
Conditions
Schizophrenia
Interventions
Risperidone, Olanzapine (enrollment closed in this treatment), Molindone
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
8 Years to 19 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
4
States / cities
Medford, Massachusetts • Chapel Hill, North Carolina • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2014 · Synced Oct 21, 2026, 1:43 PM EDT
Completed Not applicable Interventional Results available

Omega-3 Dietary Supplements in Schizophrenia

NCT01786239
View directory record Official record
Conditions
Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Bipolar Disorder, Psychosis NOS
Interventions
Risperidone, Omega-3 capsules, Placebo
Drug
Lead sponsor
Delbert Robinson
Other
Eligibility
15 Years to 40 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 21, 2026, 1:43 PM EDT
Completed Phase 4 Interventional Results available

Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder

NCT06041646
View directory record Official record
Conditions
Bipolar Disorder, Schizophrenia, Agitation,Psychomotor, Schizo Affective Disorder, Schizophreniform Disorders
Interventions
Sublingual film containing Igalmi
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Little Rock, Arkansas • Rogers, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 21, 2026, 1:43 PM EDT
Recruiting No phase listed Observational

Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services

NCT06740383
View directory record Official record
Conditions
Schizophrenia Spectrum and Other Psychotic Disorders, Schizophrenia, Delusional Disorder, Bipolar 1 Disorder, Schizoaffective Disorder, Psychosis Not Otherwise Specified, Early Psychosis
Interventions
Not listed
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 40 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
Hartford, Connecticut • Athens, Georgia • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 21, 2026, 1:43 PM EDT
Completed Not applicable Interventional

Academic-Community EPINET (AC-EPINET)

NCT04497857
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders, Major Depression With Psychotic Features, Bipolar Disorder With Psychotic Features
Interventions
Coordinated Specialty Care (CSC)
Other
Lead sponsor
Indiana University
Other
Eligibility
16 Years to 35 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
6
States / cities
Indianapolis, Indiana • New Orleans, Louisiana • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 21, 2026, 1:43 PM EDT
Completed Not applicable Interventional

Prospective Pharmacogenetic Testing and Clinical Outcomes in Patients With Early-Phase Psychosis

NCT02566057
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorders, Bipolar Disorder
Interventions
PGx testing guided treatment (PGT)
Biological
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 64 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Oct 21, 2026, 1:43 PM EDT
Completed Phase 3 Interventional Results available

Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia

NCT04268303
View directory record Official record
Conditions
Agitation, Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder, Schizophreniform Disorders
Interventions
Sublingual film containing dexmedetomidine (BXCL501), Placebo Film
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
15
States / cities
Little Rock, Arkansas • Cerritos, California • Culver City, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 21, 2026, 1:43 PM EDT
Completed No phase listed Observational Results available

Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study

NCT01269710
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorder, Not Otherwise Specified, Prodromal Schizophrenia, Mood Disorder, Bipolar Disorder, Major Depressive Disorder, Depressive Disorder, Not Otherwise Specified, Mood Disorder, Not Otherwise Specified, Autism Spectrum Disorder
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
3 Years to 19 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 22, 2013 · Synced Oct 21, 2026, 1:43 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder

NCT03187769
View directory record Official record
Conditions
Schizophrenia, Schizophreniform Disorders, Bipolar I Disorder
Interventions
ALKS 3831, Olanzapine
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
16 Years to 40 Years
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
25
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Garden Grove, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced Oct 21, 2026, 1:43 PM EDT
Completed Phase 4 Interventional Results available

Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis

NCT00320671
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole, Risperidone
Drug
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 40 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Sep 8, 2016 · Synced Oct 21, 2026, 1:43 PM EDT
Completed Not applicable Interventional Results available

Naltrexone for Antipsychotic-Induced Weight Gain

NCT01866098
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Bipolar Disorder, Severe Major Depression With Psychotic Features
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 75 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 1, 2021 · Synced Oct 21, 2026, 1:43 PM EDT
Completed Phase 2 Interventional Results available

Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents

NCT01731119
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychosis NOS, Autistic Disorder, Asperger Syndrome, Child Development Disorders, Pervasive, Bipolar I Disorder, Bipolar II Disorder, Mood Disorder NOS, Severe Major Depression With Psychotic Features, Single Episode Major Depression Without Psychotic Symptoms, Severe Mood Disorder With Psychotic Features
Interventions
Latuda©
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
6 Years to 19 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 21, 2026, 1:43 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831

NCT03201757
View directory record Official record
Conditions
Schizophrenia, Schizophreniform Disorder, Bipolar I Disorder
Interventions
ALKS 3831
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
16 Years to 70 Years
Enrollment
523 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
49
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Anaheim, California + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Oct 21, 2026, 1:43 PM EDT
Completed Not applicable Interventional Results available

Targeting Physical Health in Schizophrenia: Physical Activity Can Enhance Life Randomized Control Trial

NCT04173572
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Brief Psychotic Disorder, Schizophreniform Disorders, Unspecified Schizophrenia Spectrum and Other Psychotic Disorder
Interventions
PACE-Life, Exercise Intervention
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Oct 21, 2026, 1:43 PM EDT